TargetMol

JSH-23

Product Code:
 
TAR-T1930
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1930-1mg1mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1930-2mg2mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1930-5mg5mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1930-1mL1 mL * 10 mM (in DMSO)£146.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1930-10mg10mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1930-25mg25mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1930-50mg50mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1930-100mg100mg£434.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
JSH-23, an NF-κB inhibitor?IC50= 7.1 μM?, suppresses the transcriptional activity.
CAS:
749886-87-1
Formula:
C16H20N2
Molecular Weight:
240.35
Pathway:
NF-κb
Purity:
0.9967
SMILES:
Cc1ccc(NCCCc2ccccc2)c(N)c1
Target:
NF-κB

References

1. Shin HM, et al. FEBS Lett. 2004, 571(1-3), 50-54. 2. Arias-Salvatierra D, et al. Cell Signal. 2011, 23(2), 425-435. 3. Kasparkova J, et al. FEBS J. 2014, doi: 10.1111/febs.12711. 4. Kumar A, et al. Diabetes Obes Metab. 2011, 13(8), 750-758. 5. Song H, Tang X, Li X, et al. HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-?B and Epithelial?Mesenchymal Transition[J]. Drug Design, Development and Therapy. 2020, 14: 4291. 6. Lai X, Wang M, Zhu Y, et al. ZnO NPs delay the recovery of psoriasis-like skin lesions through promoting inflammation and keratinocyte apoptosis via nuclear translocation of phosphorylated NF-?B p65 and cysteine deficiency[J]. Journal of Hazardous Materials. 2020: 124566.